Stonefly news
- 10/01/08 - inVentiv Health Selected to Provide Integrated Marketing Services for GeneraMedix Inc.
- 9/23/08 - Stonefly Communications Group and Strategyx, LLC Win Strategic Assignment with GeneraMedix Inc.
- 8/7/08 - President and CEO of Stonefly Communications Group Receives Industry Honor
- 7/10/08 - Stonefly Communications Group Wins Assignment with Life Line Screening
- 7/17/08 - Stonefly Communications Group Serves Up "It's Launch Time!"
- 6/6/08 - Stonefly Welcomes New Members
- 5/1/08 - Stonefly Communications Group Launches New Ad Campaign
- 4/12/08 - Stonefly Wins Five-Year Agency-of-Record Assignment with Patheon
- 2/1/08 - Stonefly Wins Three-Year Agency-of-Record Assignment for Leading Global Medical Food Manufacturer
- 1/7/08 - Stonefly Communications Group Honored at RX Club Show
- 1/7/08 - Stonefly Communications Honored at 2007 Global Awards
- 2/7/07 – Stonefly Wins Assignment with ZymoGenetics' RECOTHROM™
| 9/23/08 - Stonefly Communications Group and Strategyx, LLC Win Strategic Assignment with GeneraMedix Inc. |
|
InVentiv Health Agencies Partner to Maximize Value of New Epoprostenol Therapy COLUMBUS, Ohio – September 23, 2008 – Stonefly Communications Group, an inVentiv Health company (NASDAQ: VTIV) and a patient-focused, insight-driven healthcare advertising agency and Strategyx, LLC, recently were selected to help maximize the value of a new specialty Epoprostenol therapy for GeneraMedix Inc., a pharmaceutical company that develops, markets and distributes generic injectable products. "GeneraMedix Inc. has built a solid reputation in the generic injectable market and now has an opportunity with a specialty brand in a unique market," said John Racik, President and CEO of Stonefly Communications Group. "When the leadership team at GeneraMedix was searching for communication partners to conduct brand positioning and market research to drive the value of its new FDA-approved room temperature Epoprostenol product, it selected Stonefly and Strategyx to deliver key market insights. We're excited to be a part of the GeneraMedix team," added Racik. GeneraMedix's Epoprostenol for Injection 1.5 mg therapy is indicated for the long-term treatment of primary pulmonary hypertension and pulmonary hypertension associated with NYHA Class III and Class IV patients who do not respond adequately to conventional therapy. "We are thrilled to be working with Stonefly and Strategyx," said Robin Smith Hoke, President, Commercial Operations, of GeneraMedix. "Their extensive branding and communications experience, coupled with their deep understanding of marketing specialty brands, makes them an ideal strategic partner." "GeneraMedix has an exciting new specialty brand in a competitive category," said Amber Gilbert, Managing Director of Strategyx, LLC. "We are confident we can leverage our deep expertise in pricing and launching specialty injectables to help GeneraMedix navigate payer, patient and physician challenges and realize the full value of this therapeutic asset. We're looking forward to a very successful partnership." About Stonefly Communications Group Stonefly Communications Group is an insight-focused, marketing, advertising and communications agency dedicated to redefining success for its clients around the world. With a promise to continually innovate, Stonefly's client advisors and creative champions develop actionable strategies that engage audiences with bold strategic, tactical and creative solutions. See how Stonefly can help you BelieveinhealthSM by visiting www.stoneflygroup.com About Strategyx, LLC Strategyx is a leading strategy consulting firm dedicated to the pharmaceutical and biotechnology industries. Strategyx helps clients develop actionable strategies and deliver clear results in four key practice areas: Market Strategy, Brand Strategy, Organization Design and New Product Planning. Strategyx's deep understanding of the factors that define product profitability across the U.S. and international markets has led to successful, long-term partnerships with pharmaceutical and biotechnology clients of all sizes. Find out more at www.strategyx.net About GeneraMedix Inc. GeneraMedix Inc. is a privately held pharmaceutical company offering high quality generic injectable products to the U.S. hospital and specialty markets. In addition to its products already marketed, GeneraMedix has a significant number of injectable products under development, as well as a number of products currently under FDA review. Headquartered in Liberty Corner, New Jersey, the company was founded in July of 2004. Additional information is available on the company's website at www.generamedix.com About inVentiv Health inVentiv Health (NASDAQ: VTIV) is the leading provider of commercialization and complementary services to the healthcare industry globally. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial and inVentiv Patient Outcomes. inVentiv Health's client roster comprises more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including the top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors. |
